Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Candel Therapeutics Inc. | CAN-2409 - (ULYSSES) | Prostate Cancer (Active Surveillance) | Phase 3 | Data Released | intratumoral | Oncology |
| Candel Therapeutics Inc. | CAN-2409 | Glioma | Phase 3 | Trial Discontinued | Intratumoral | Oncology |
| Candel Therapeutics Inc. | CAN-2409 (aglatimagene besadenovec) combined with Valacyclovir | Prostate cancer | Phase 3 | Ongoing | Intratumoral and oral | Oncology |
| Candel Therapeutics Inc. | CAN-2409 plus valacyclovir (prodrug) | Non-Metastatic Pancreatic Cancer, Pancreatic ductal adenocarcinoma (PDAC) | Phase 2 | Ongoing | Intratumoral plus oral | Oncology |
| Candel Therapeutics Inc. | CAN-2409 + valacyclovir | Non-small cell lung cancer (NSCLC) | Phase 2 | Data Released | intratumoral oral | Oncology |
| Capricor Therapeutics Inc. | Deramiocel (CAP-1002) - (INSPIRE) | COVID-19 | Phase 2 | Data Released | Intracoronary | COVID-19 |
| Capricor Therapeutics Inc. | CAP-1002 - (ALLSTAR) | Myocardial infarction (heart attack) | Phase 2 | Trial Discontinued | Intracoronary | Cardiology |
| Capricor Therapeutics Inc. | CAP-1002 - (HOPE-3) | Duchenne Muscular Dystrophy (DMD) | Phase 3 | Ongoing | Intracoronary | Genetic Disorder |
